There is only a little information about survival in newly registered blind subjects. Methods. A closed cohort of blind subjects (n = 2680, 1803 of them women), newly registered between 1990 and 1993 in the district of Wurttemberg-Hohenzollern, Germany, was observed for up to 48 months. Mortality was compared to that of the general population. Predictors of mortality within that cohort were identified by Cox proportional hazards regression analysis.
The objective of this study was to estimate the survival function in a cohort of newly registered blind subjects, to identify predictors of mortality, and to compare mortality in diabetic and non-diabetic subjects within this cohort. Furthermore, it was our purpose to compare the mortality in this cohort with that of the general population.
There are only a few studies investigating survival in newly registered blind subjects. A study of more than 11 000 policy holders with Metropolitan Life Insurance who were granted blindness allowances during 1923-1933 revealed 2.5-fold death rates compared with all policy holders. 1 In the 1960s, Berkow et al. 2 studied survival in a series of 180 blind diabetic patients who had received guide dogs. Their results suggested a very poor life expectancy for blind diabetic individuals. Rogot et al? compared death rates in over 11 000 people first registered as legally blind in Massachusetts between 1940 and 1959 with those of the general population. They found poorer survivorship in the blind than in the general population up to the age of 75 with little difference at older ages. Survival in people with diabetes was extremely low, even lower than in all other blind people. However, those studies did not differentiate among diabetic individuals according to whether diabetes was the only or a contributory cause of blindness, or was unrelated to the blindness. Therefore, survival in the blind with diabetes deserves a more detailed investigation.
In Germany, almost all blind people are entitled by law to receive a blindness allowance independent of sources of income. 4 Because it is a substantial amount (between 500 and 1000 German marks per month), one can assume that almost all the eligible apply for this blindness allowance and are registered accordingly. We 8 Per cent of all subjects in the column. b Per cent of all diabetic subjects in the column.
used a register of blindness allowance recipients to study survival in a nearly complete sample of incident cases of blindness in one German district.
SUBJECTS AND METHODS

Definition and Follow-Up of Study Cohort
In one district of Germany (Wiirttemberg-Hohenzollern, approximately 5.4 million inhabitants), a list of all those newly registered as blind (blindness allowance recipients) with the welfare administration between 1 January 1990 and 31 December 1993 was drawn up. All those who applied for registration as blind and met the criteria for blindness according to the Federal Ministry of Labour and Welfare 5 ' 6 (visual acuity of 1/50 or less in the better eye, visual field reduced to a radius of 5°o r less, or similar reduction of vision, e.g. due to central scotoma, making the person unable to find his or her way) were included. The decision was based on written medical and ophthalmological reports. Each record of an identified subject was searched for date of birth, date of registration, sex, ophthalmological findings, and whether diabetes was present. In all cases with diabetes, an experienced ophthalmologist (FP) determined whether diabetes was the only cause of blindness or one of several contributory causes, or whether blindness was not due to diabetes. From the record it was also determined whether the person had died before 1 February 1994. Vital status could be ascertained because the blindness allowance is paid every month until the person dies or moves out of the area. Those who moved were censored at the time of moving. In this way, a closed cohort of incident cases of blindness was generated which could be followed for up to 48 months. Survival time was calculated as month of death minus month of registration as blind.
Statistical Analysis
The survival function was estimated using the KaplanMeier method. 7 Differences in survival functions between subgroups were tested by the logrank test. 7 We fitted a proportional hazards (Cox) model to determine the relationship between mortality as the outcome variable, and age, sex, diabetes and cause of blindness in diabetic subjects as predictor variables. 7 In addition, the mortality of the study population was compared externally to the entire population of the federal German state of Baden-Wiirttemberg. Mortality data for this state were obtained from the Statistical Office. Age-and sex-specific relative mortality risks were calculated. Using the direct method of standardization, comparative mortality figures (CMF), 8 ' 9 together with their 95% confidence intervals (CI), were estimated according to Rothman. 10 In addition, using the indirect method of standardization, standardized mortality ratios (SMR) were calculated. 8 " 10 All calculations were carried out with the SAS statistical package (version 6.09).
The significance level at all analyses was a = 0.05.
RESULTS
There were 2714 people newly registered as blindness allowance recipients in the defined period. Because of missing values on the predictor variables considered, 34 of them were excluded from the analysis. Therefore, the cohort studied consisted of 2680 subjects, 582 of whom died up to January 1994. The distribution with respect to sex, age, diabetic status, and cause of blindness in diabetic individuals is shown in Table 1 . In total, there were 57 344 person months of observation. A crude incidence rate of death of 12 179 per 100 000 per year was estimated. The mean observation time was 21.4 months (SD 13.1, maximum 48). Before the end of Figure 1 . The probability of survival after 47 months was 0.64 (95% CI : 0.59-0.70) in the nondiabetic, and 0.46 (95% CI : 0.37-0.55) in the diabetic subjects. In a univariate analysis, the survival functions were significantly different between diabetic and nondiabetic individuals (P < 0.0001).
The results of the regression analysis are shown in Table 2 . When all subjects were combined, predictors of increased mortality in the regression model were age, male sex and diabetes. All of the possible predictors were statistically significant. The increase in risk was greater in those diabetic subjects whose cause of blindness was related to diabetes, compared with diabetic individuals with other causes of blindness. There was only a slight difference in the risk ratio [RR] (with widely overlapping confidence intervals) between subjects with diabetes as the only cause, and subjects with diabetes as a contributory cause of blindness. The same pattern was found when men and women were analysed separately. The RR were greater in women than in men, however. With fewer deaths in men (179 versus 403 in women) the confidence intervals are wider and the variables 'blindness unrelated to diabetes' and 'diabetes contributory cause of blindness' fail to be statistically significant.
Comparative mortality figures and SMR are shown in Table 3 . Due to zero person-years of observation in some age-and sex-specific strata, CMF could not be calculated for some subgroups of diabetic subjects. Mortality was considerably increased in the blind cohort, mainly in those who had diabetes. Differences between SMR and CMF in the same subgroup are explained by the different age distribution of the population to which they are standardized (the general population for CMF, the subgroup considered for SMR).'° (Where possible, the comparison of subgroups according to CMF is preferable because of the common standard inherent in this measure.) The SMR and CMF were also analysed separately for men and women (Table 4 ). The higher CMF for men are explained by their younger mean age. Age-specific RR of death, compared with the general population, are shown in Table 4 . The RR were high in the younger age groups and decreased with increasing age. This pattern was found in all subgroups (men and women, non-diabetic subjects, diabetic subjects with cause of blindness related or unrelated to diabetes). In some subgroups, the RR increased again slightly in the oldest age group.
DISCUSSION
We compared mortality in a cohort of newly registered blind with that of the general population, and identified predictors of mortality within that cohort. Very few people may have become blind without being entitled to blindness allowance. The rare exceptions include blindness due to occupational diseases and industrial accidents, as well as blindness during imprisonment. According to the professional associations liable for industrial safety and insurance, less than 10 people per year become blind due to occupational diseases and industrial accidents in the whole of Germany. Probably a few subjects meeting the criteria of blindness did not apply for blindness allowance. Although there is no information about those who did not apply, due to the unique and substantial financial incentive for registration, the registry can be considered to include a much greater proportion of the blind than registries in other countries. 3 " Some subjects had to be excluded for missing values. With these qualifications, the study population may be considered to be an almost complete sample of incident cases of blindness in the study area during the period of observation. In univariate analysis, the survival curves show a great difference between diabetic and non-diabetic individuals. Also in the regression model, increasing age and the presence of diabetes increased the risk of death, as would be expected. Diabetes as the cause of blindness further increased the risk of death compared with subjects who had diabetes but had other causes of blindness. When the study population was compared with the general population, the relative mortality risk in the diabetic blind was considerably higher than the approximately twofold mortality risk of individuals with type 2 diabetes as compared with the general population."' 12 These findings are in accordance with previous studies showing a high excess mortality in blind subjects, especially those who became blind from diabetic retinopathy. 1 ' 3 As in previous studies, the excess risk of death decreased considerably with increasing age. 1 ' 3 Apparently this pattern has not substantially changed over the last 60 years.
However, the RR of death compared with the general population was higher in our study than in that conducted in Massachusetts (SMR for all blind subjects: 2.005 in our investigation, 1.45 in the Massachusetts registry, although the blind in Massachusetts were younger than our cohort 3 ). The relative mortality risk was also higher than in the Metropolitan Life Insurance study (SMR 2.47 with a considerably younger age distribution than in both of the other studies 3 ) under the age of 75 years. This difference may be due to the more rigid definition of legal blindness in Germany (vision with correction of 20/200 or less in the better eye in the USA 3 ) resulting in a selection of severe cases. Another explanation may be underascertainment of severe cases, e.g. those living in nursing homes, in the Massachusetts study. It is also possible that due to improved prevention of blindness only people with the severest underlying diseases have become blind in recent years, or that severely ill people live longer with a greater cumulative probability of becoming blind.
Some limitations to the design and the results of this study have to be considered. We had to rely on the information laid down in the records and provided by the administration. Therefore, the number of variables we could study was limited. For example, information about possible confounders like smoking and duration of diabetes was not available. Some misclassification of diabetic status is possible.
There are few population-based studies of the incidence and causes of blindness, as well as the risk of blindness attributable to diabetes." Ongoing studies of data from blindness allowance registers' 3 may shed some light on this issue in the future. In the cohort studied here, with respect to causes of blindness, diagnoses and descriptions of findings were given, but a standardized classification system was not used. In diabetic subjects we were able to distinguish between those whose blindness was probably due to diabetic retinopathy, and those whose blindness was unrelated to diabetes. We do not report a detailed description of other causes of blindness, however, due to diagnostic uncertainty.
A considerable number of diabetic subjects apparently became blind for other reasons than diabetic retinopathy. Although there may be some misclassification of causes of blindness, our findings are plausible given the age of most subjects studied here. One may conclude that in addition to diabetic status, the cause of blindness in diabetic individuals is a major predictor of mortality. 
